Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165402 | 0.89 | GAA (0.64) | GAAMEN1KMT2ALMNAKDM4E | |
| SCHEMBL5164806 | 0.80 | MEN1 (0.53) | GAAMEN1KMT2ALMNAKDM4E | |
| SCHEMBL5163986 | 0.80 | MEN1 (0.52) | GAAMEN1KMT2ALMNAKDM4E | |
| SCHEMBL30733139 | 0.80 | MEN1 (0.52) | GAAMEN1KMT2ALMNAKDM4E | |
| SCHEMBL5166737 | 0.80 | L3MBTL1 (0.45) | MEN1KMT2AKDM4ETDP1SMN1; SMN2 | |
| SCHEMBL6429618 | 0.80 | LMNA (0.57) | KMT2ALMNAPOLBHTTSMN1; SMN2 | |
| SCHEMBL3564486 | 0.77 | L3MBTL1 (0.64) | KDM4EPOLBSMN1; SMN2ALDH1A1RXFP1 | |
| SCHEMBL4617734 | 0.75 | ALDH1A1 (0.63) | MEN1KMT2ALMNAKDM4EPOLB | |
| SCHEMBL5165342 | 0.74 | ALDH1A1 (0.52) | GAAMEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL5165214 | 0.74 | MEN1 (0.48) | GAAMEN1KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765332-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | GAA 2148/4885MEN1 4371/4885KMT2A 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.